Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 499 across all filing types
Latest filing 2024-05-27 AGM Information
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Kallelse till årsstämma i Hansa Biopharma AB (publ)
AGM Information Classification · 100% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and explicitly states "Kallelse till årsstämma i Hansa Biopharma AB (publ)" (Notice of Annual General Meeting in Hansa Biopharma AB (publ)). It details the date, time, location, registration procedures (including proxy voting and advance voting), and the full proposed agenda for the meeting. The agenda items cover standard AGM topics like election of the chairman, approval of financial statements, election of the board and auditors, determination of remuneration, and proposals for incentive programs. This content is the definitive material sent out to shareholders to inform them about and solicit their participation/votes for the Annual General Meeting. Therefore, the correct classification is AGM-R (AGM Information).
2024-05-27 Swedish
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for an instrument ('Aktier') by a holder ('Avanza Bank Holding AB') involving specific share quantities, voting rights, and dates (03/05/2024 transaction date, 06/05/2024 published date). The text explicitly mentions 'Reason for major shareholding notification' and 'Flaggning sker för passerat tröskelvärde beträffande det aggregerade innehavet' (Flagging occurs due to crossing the threshold regarding the aggregate holding). This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to code MRQ.
2024-05-06 English
Correction: Hansa Biopharma: increase in number of shares and votes
Share Issue/Capital Change Classification · 98% confidence The document is a press release titled "Correction: Hansa Biopharma: increase in number of shares and votes." It explicitly states that the company's registered share capital and number of shares increased due to the issuance of new ordinary shares. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). Although it is a press release, the core subject matter is a capital change, making SHA more specific than a general Regulatory Filing (RNS) or Report Publication Announcement (RPA). The document length is short (2451 chars), but it is the primary announcement of the event, not just an announcement *about* an attached report.
2024-05-03 English
Hansa Biopharma: increase in number of shares and votes
Share Issue/Capital Change Classification · 100% confidence The document is a press release from Hansa Biopharma announcing an increase in the total number of registered shares and votes following a new share issue. This type of corporate action, specifically regarding changes to share capital and share counts, falls under the category of Share Issue/Capital Change.
2024-05-03 English
Hansa Biopharma: Ökning av antalet aktier och röster
Share Issue/Capital Change Classification · 99% confidence The document is a press release from Hansa Biopharma dated May 3, 2024, announcing an increase in the number of shares and votes due to a recent share emission. The text explicitly details the change in registered share capital and the total number of shares (including common and C-shares) and votes as of the current date. This directly relates to changes in the company's capital structure, specifically the issuance of new shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific capital event.
2024-05-03 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport för januari–mars 2024' (Interim Report for January–March 2024). It contains comprehensive financial tables (income statement, cash flow, balance sheet items), management commentary ('VD har ordet'), and detailed operational updates for the specified quarterly period. It is a substantive financial report rather than a mere announcement or certification, fitting the definition of an Interim/Quarterly Report. Q1 2024
2024-04-18 Swedish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.